Related Experiment Video
Updated: Mar 6, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Pathophysiology and Therapeutic Options for Fecal Incontinence
Alexandra Guillaume1, Ahmed E Salem, Patricia Garcia
1*Department of Medicine, Division of Gastroenterology and Hepatology, Stony Brook University Medical Center, Stony Brook†Department of Medicine, University of Rochester Medical Center, Rochester§Department of Medicine, Division of Gastroenterology and Hepatology, Lenox Hill Hospital, Northwell Health System, New York, NY, USA‡Department of Medicine, Division of Gastroenterology and Hepatology, The Johns Hopkins Medical Institutions, Baltimore, MD.
Abstract:
Fecal incontinence (FI), defined as the involuntary loss of solid or liquid feces through the anus is a prevalent condition with significant effects on quality of life. FI can affect individuals of all ages and in many cases greatly impairs quality of life but, incontinent patients should not accept their debility as either inevitable or untreatable. The severity of incontinence can range from unintentional elimination of flatus to the complete evacuation of bowel contents. It is reported to affect up to 18% of the population, with a prevalence reaching as high as 50% in nursing home residents. However, FI is often underreported, thus obscuring its true prevalence in the general population. The options for treatment vary according to the degree and severity of the FI. Treatment can include dietary and lifestyle modification, certain medications, biofeedback therapy, bulking agent injections, sacral nerve stimulation as well as various types of surgery. In this article, we aim to provide a comprehensive review on the diagnosis and management of FI.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome III: Medical and Nursing Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

